CUBE vs STOK · P/E 25, rev $1.07B vs rev $36.6M
CubeSmart (CUBE) versus Stoke Therapeutics Inc (STOK) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Stoke Therapeutics Inc (STOK) is a biotechnology company listed on NASDAQ.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported STOK revenue for 2024-12-31 was $36.6M. Net income was -$89.0M. Revenue was up 316.3% from 2023-12-31 to 2024-12-31. STOK currently screens at market cap $1.88B.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. STOK currently screens at market cap $1.88B.
Not investment advice. Open the CUBE and STOK stock pages for the full models.
Not investment advice.